Institut Catala D'oncologia

At Institut Catala D'oncologia, a major share of the research portfolio focuses on oncology, especially neoplasms and advanced solid cancers. Studies span breast cancer, non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancers, ovarian cancer, pancreatic cancer, and urothelial carcinoma. The trials are largely designed to test new treatments, compare them with current standards, and improve outcomes for patients with difficult-to-treat or metastatic disease.

• Testing new targeted and immune-based therapies for advanced solid tumors
• Comparing treatment strategies in metastatic and recurrent cancers
• Improving control of tumor progression and extending survival

This broad activity reflects a strong emphasis on finding more effective options for patients with cancers that have spread or returned after earlier treatment.

A large part of the site’s clinical research is dedicated to hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes, chronic lymphocytic leukemia, multiple myeloma, and a wide range of lymphomas. These studies aim to refine treatment for relapsed, refractory, and newly diagnosed blood cancers, while also exploring ways to deepen responses and reduce disease burden.

• Evaluating novel therapies for leukemia, lymphoma, and myeloma
• Studying treatment options for relapsed or hard-to-treat blood cancers
• Assessing strategies to improve remission rates and long-term control

The Institut Catala D'oncologia also contributes to research in transplant-related and immune-related blood disorders, strengthening its role in complex cancer care.

The site has extensive trials in breast cancer, covering early-stage, locally advanced, and metastatic disease, with special attention to HER2-positive, HER2-negative, and hormone receptor-positive subtypes. Research here is aimed at testing new combinations, improving adjuvant and neoadjuvant treatment, and identifying which patients are most likely to benefit from specific therapies.

• Studying targeted and endocrine-based approaches for different breast cancer subtypes
• Comparing new treatment combinations with established care
• Seeking better ways to personalize therapy and improve response

These trials reflect a strong interest in tailoring care to tumor biology and disease stage, with the goal of improving outcomes while avoiding unnecessary treatment.

Another major research area is lung cancer, especially non-small cell lung cancer and small cell lung cancer. Trials include patients with resectable, advanced, and metastatic disease, and often focus on EGFR, ALK, ROS1, and KRAS-driven tumors. The purpose is to improve survival, reduce recurrence, and identify better treatment options for patients with limited alternatives.

• Testing targeted therapies and immunotherapies in lung cancer
• Evaluating treatment after surgery to lower the risk of relapse
• Exploring biomarker-guided approaches for more precise care

This area shows a clear focus on both earlier-stage and advanced thoracic cancers, with research aimed at making treatment more effective and better matched to tumor features.

Research in digestive system diseases is well represented, including colorectal cancer, gastric cancer, gastroesophageal junction cancer, pancreatic cancer, hepatocellular carcinoma, and biliary tract cancer. The trials are mainly designed to test new therapies, compare combinations, and improve disease control in cancers that are often diagnosed at an advanced stage.

• Evaluating new treatment options for gastrointestinal and liver tumors
• Studying biomarker-linked approaches in pancreatic and colorectal cancer
• Comparing therapies to improve response and delay progression

This research portfolio supports better treatment selection across several difficult gastrointestinal cancers, including advanced and metastatic disease.

The site also runs studies in melanoma, head and neck squamous cell carcinoma, ovarian cancer, renal cell carcinoma, prostate cancer, and other solid tumors. Many of these trials examine immunotherapy, targeted treatment, and combination strategies to improve tumor response and help manage recurrent or metastatic disease.

• Testing immune-based and targeted treatments across multiple tumor types
• Assessing options for recurrent, metastatic, or treatment-resistant cancers
• Supporting biomarker-driven research for more individualized care

Across these areas, the research at Institut Catala D'oncologia aims to expand treatment choices for patients with cancers that remain challenging despite current standards of care.

Beyond direct cancer treatment, the portfolio includes studies in graft-versus-host disease, immune system processes, and related supportive care topics. These trials explore ways to improve recovery after transplant, manage immune complications, and support patients undergoing intensive cancer therapy.

• Improving care for transplant-related complications
• Evaluating therapies for immune-driven disorders linked to cancer treatment
• Supporting safer and more effective long-term cancer care

This area highlights the site’s broader commitment to the full treatment journey, not only tumor control but also the management of treatment-related effects.